✦ LIBER ✦

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

✍ Scribed by Michael K. Samson; Saul E. Rivkin; Stephen E. Jones; John J. Costanzi; Albert F. Lobuglio; Ronald L. Stephens; Edmund A. Gehan; Glenn D. Cummings

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 565 KB
Volume: 53
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19840301)53:5<1029::aid-cncr2820530503>3.0.co;2-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Amifostine does not protect against the

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors : A children's oncology group study

✍ Neyssa Marina; Kay W. Chang; Marcio Malogolowkin; Wendy B. London; A. Lindsay Fr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

Early versus late intensification for pa

Early versus late intensification for patients with high-risk Hodgkin lymphoma—3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation : Five-year results of a randomized trial on behalf of the GOELAMS group

✍ Nina Arakelyan; Christian Berthou; Bernard Desablens; Sophie de Guibert; Vincent 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views